| Treatments with nirogacestat |
2023-10-20 |
2024-2-29 |
|
| Treatments with nirogacestat |
2023-10-20 |
2024-2-15 |
|
| Chlorinated tetralin compounds and pharmaceutical compositions |
2023-10-20 |
2024-2-22 |
|
| Non-linear dosing of mirdametinib |
2023-8-02 |
2024-1-04 |
|
| Treatment of multiple myeloma |
2023-7-26 |
2024-2-01 |
|
| Determination of bcma level on plasma cells by flow cytometry |
2023-7-26 |
2024-2-01 |
|
| 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of yap/taz-tead … |
2023-4-27 |
2023-8-18 |
|
| Combination and the use thereof |
2023-4-26 |
2023-11-02 |
|
| Synthesis of nirogacestat |
2023-4-20 |
2023-10-05 |
|
| Discovery of covalent egfr inhibitor through cysteine 775 |
2023-4-05 |
2023-10-12 |
|
| Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
2023-3-16 |
2023-9-21 |
|
| Fluorinated Phenylamino Compounds and Pharmaceutical Compositions |
2023-3-16 |
2023-9-21 |
|
| Treatment of tuberous sclerosis with mirdametinib |
2023-3-16 |
2023-9-21 |
|
| Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead |
2023-2-24 |
2023-11-01 |
|
| Combination therapy for b-cell disorders |
2023-2-17 |
2023-8-24 |
|
| Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead |
2023-2-02 |
2024-1-18 |
|
| Treatment of ovarian cancer with nirogacestat |
2023-2-01 |
2023-8-10 |
|
| Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2- … |
2023-1-09 |
2023-10-19 |
|
| Tetrahydrobenzoazepinones and related analogs for inhibiting yap/taz-tead |
2022-12-23 |
2023-9-01 |
|
| Spiros and related analogs for inhibiting yap/taz-tead |
2022-12-23 |
2023-9-01 |
|
| Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead |
2022-12-23 |
2023-9-01 |
|
| 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead |
2022-12-23 |
2023-10-16 |
|
| Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD |
2022-12-23 |
2023-6-29 |
|
| Compositions of solid forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4- … |
2022-11-21 |
2023-5-11 |
|
| Compositions and treatments with nirogacestat |
2022-11-04 |
2023-6-08 |
|
| Co-administration of mirdametinib and lifirafenib for use in the treatment of … |
2022-11-03 |
2023-5-08 |
|
| Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl … |
2022-10-24 |
2023-3-23 |
|
| Covalent egfr inhibitors and methods of use thereof |
2022-10-18 |
2023-4-27 |
|
| Combinations of anti-bcma car t cells and gamma secretase inhibitors |
2022-10-13 |
2023-4-20 |
|
| A combination therapy with nirogacestat and a bcma-targeted therapy and uses of … |
2022-10-10 |
2023-2-16 |
|
| Methods of treating multiple myeloma |
2022-9-20 |
2023-3-30 |
|
| Chlorinated tetralin compounds and pharmaceutical compositions |
2022-9-08 |
2023-3-16 |
|
| Synthesis of nirogacestat |
2022-9-01 |
2023-3-09 |
|
| Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2 … |
2022-6-14 |
2023-2-02 |
|
| CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2 … |
2022-2-17 |
2023-5-17 |
|
| DISPERSIBLE FORMULATIONS OF N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2- … |
2022-2-17 |
2023-5-17 |
|
| POLYTHERAPIES COMPOSED BY CHIMERIC ANTIGEN RECEPTORS WHICH ACT SELECTIVELY ON … |
2021-1-15 |
2022-4-13 |
|
| Combination therapies of chimeric antigen receptors targeting b-cell maturation … |
2021-1-15 |
2021-11-01 |
|
| Combination therapy with anti-BCMA antibodies and gamma secretase inhibitors |
2020-4-09 |
2022-1-11 |
|
| Monolithic sputter target backing plate with integrated cooling passages |
2006-8-01 |
2007-3-01 |
|
| Equivalent primary display |
2006-2-14 |
2006-8-17 |
|
| Deposition of licoo2 |
2005-12-07 |
2007-8-29 |
|
| Mode size converter for a planar waveguide |
2005-4-06 |
2005-8-25 |
|
| Solid state light engine optical system |
2003-4-24 |
2006-12-26 |
2006-12-26 |
| Composes de tetraline chloree et compositions pharmaceutiques |
2022-9-08 |
2023-3-16 |
|
| Synthese de nirogacestat |
2022-9-01 |
2023-3-09 |
|